Rituximab Effective in Myasthenia Gravis

14/04/2010 10:00

A research group from Yale University have found promising evidence that the anti-CD20 antibody decreases B-cell activation, markedly reduces auto-antibody titers and improves symptoms in patients with myasthenia gravis (MG) unresponsive to current therapies. For more information see http://www.medpagetoday.com/MeetingCoverage/AAN/19555